We are advising Vistagen Therapeutics, Inc. (NASDAQ: VTGN) investors that the firm is investigating potential legal claims arising from alleged false statements about Vistagen’s drug candidate fasedienol. Current shareholders are encouraged to contact the firm.
Read More